Dr. Jonathan Kimmelman, assistant professor of the Biomedical Research unit at McGill University, discusses with host Dr. Maurice Pickard what appears to be a ‘job' that may exploit the underclass in Phase 1 clinical studies. The poor in the studies are less likely to have access to the drugs when approved, which calls the risk/benefit ratio into question. Do for-profit research companies and for-profit Institutional Review Boards provide adequate protection for the rights of the volunteers?
Unfair Treatment of Phase I Clinical Trial Subjects
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Dr. Jonathan Kimmelman, assistant professor of the Biomedical Research unit at McGill University, discusses with host Dr. Maurice Pickard what appears to be a ‘job' that may exploit the underclass in Phase 1 clinical studies. The poor in the studies are less likely to have access to the drugs when approved, which calls the risk/benefit ratio into question. Do for-profit research companies and for-profit Institutional Review Boards provide adequate protection for the rights of the volunteers?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?